Deidre Dalmas Wilk

Deidre Dalmas Wilk

Auto-generated profile, based on publicly available information

Deidre Dalmas Wilk

Boehringer Ingelheim, Collegeville, Pennsylvania, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2011 in Toxicology and Applied Pharmacology
Verified
Journal Article
Closed access
DDDeidre A. Dalmas
Deidre A. Dalmas
MSMarshall S. Scicchitano
Marshall S. Scicchitano
DMDavid Mullins
David Mullins
AHAngela Hughes-Earle
Angela Hughes-Earle
KTKay Tatsuoka
Kay Tatsuoka
HTHeath C. Thomas
Heath C. Thomas

1 April 2008 in Toxicologic Pathology
Verified
Journal Article
Open access
PDF file
DDDeidre A. Dalmas
Deidre A. Dalmas
MSMarshall S. Scicchitano
Marshall S. Scicchitano
YCYifeng Chen
Yifeng Chen
JKJanice Kane
Janice Kane
RMRosanna Mirabile
Rosanna Mirabile
RBRogely W. Boyce
Rogely W. Boyce
Transcriptional profiling of specific elements of vasculature from animal models of vascular toxicity is an approach to gain insight into molecular mechanisms of vascular injury. Feasibility of using laser capture microdissection (LCM) to evaluate differential gene expression in selected elements of mesenteric arteries (MA) from untreated rats and rats given a single vasotoxic dose of 100 mg/kg Fenoldopam and euthanized 1 or 4 hours postdose was assessed. Regions of MA (endothelial cells [EC] and vascular smooth muscle cells [VSMC]) were selectively microdissected from optimal-cutting-temperature (O.C.T.)-embedded-frozen tissue sections. RNA was isolated, linearly amplified (LA), and hybridized to Affymetrix GeneChips®. Enrichment for specific vascular elements was evident by unique gene-expression profiles. Statistical analysis indicated that Fenoldopam treatment resulted in differential expression of 333 versus 458 genes in EC and 371 versus 618 genes in VSMC at the 1-hour or 4-hour time point, respectively. Analysis of regulated EC and VSMC genes common to both time points identified several gene functions or pathways affected by treatment. Several genes were identified in EC and/or VSMC that have not been previously linked to vascular structure or function. These data indicate that tissue–element-enrichment by LCM in conjunction with LA and GeneChip analysis offers a refined approach for assessment of injury-mediated transcriptome changes in distinct elements of the vasculature.

15 September 2025 in Toxicological Sciences
Verified
Journal Article
Open access
DRDavid Rouquié
David Rouquié
ABAndreas Bender
Andreas Bender
JCJaime Cheah
Jaime Cheah
CCChristine E Crute
Christine E Crute
DDDeidre Dalmas
Deidre Dalmas
ACAnne E Carpenter
Anne E Carpenter
Next Generation Risk Assessment (NGRA) aims to improve safety testing of pharmaceuticals, agrochemicals, and industrial chemicals. NGRA employs new approach methodologies, such as novel in vitro assays coupled with exposure modeling, to minimize the use of animal models, which can fail to predict specific biological effects in humans. The strategy of the ‘Omics for Assessing Signatures for Integrated Safety (OASIS) Consortium combines multi-omics technologies (including transcriptomics, proteomics, and Cell Painting [high-content imaging]) and multiple cell model systems (ranging from simple cell cultures to complex organotypic models). By integrating these approaches with internal exposure estimates, the consortium aims to improve the translation between in vitro and in vivo test systems, ultimately enhancing the relevance of safety assessment to human biology. OASIS’s integrated approach aims to better translate the biological effects across different chemical and biological spaces, starting with the liver as a use case. By using compounds with well-characterized in vivo and in vitro nonclinical safety and toxicology data related to adverse organ-specific effects in rats and humans, OASIS aims to create novel integrated methods that improve safety assessment while reducing animal use. Ideally, these efforts will contribute to regulatory science across sectors and support the adoption of more predictive, efficient, and cost-effective toxicological models.

18 July 2023 in Toxicological Sciences
Verified
Journal Article
Closed access
PDF file
WSWilliam Stebbeds
William Stebbeds
KRKavita Raniga
Kavita Raniga
DSDavid Standing
David Standing
IWIona Wallace
Iona Wallace
JBJames Bayliss
James Bayliss
JFJo Francis
Jo Francis
Cardiovascular toxicity is an important cause of drug failures in the later stages of drug development, early clinical safety assessment and even post-market withdrawals. Early-stage in vitro assessment of potential cardiovascular liabilities in the pharmaceutical industry involves assessment of interactions with cardiac ion channels, as well as induced pluripotent stem cell derived cardiomyocyte based functional assays, such as calcium flux and, multi-electrode-array assays. These methods are appropriate for the identification of acute functional cardiotoxicity but structural cardiotoxicity, which manifests effects after chronic exposure, is often only captured in vivo. CardioMotion is a novel, label-free, high throughput, in vitro assay and analysis pipeline which records and assesses the spontaneous beating of cardiomyocytes and identifies compounds which impact beating. This is achieved through the acquisition of brightfield images at a high framerate, combined with an optical flow-based python analysis pipeline which transforms the images into waveform data which are then parameterized. Validation of this assay with a large dataset showed that cardioactive compounds with diverse known direct functional and structural mechanisms-of-action on cardiomyocytes are identified (sensitivity = 72.9%), importantly, known structural cardiotoxins also disrupt cardiomyocyte beating (sensitivity = 86%) in this method. Furthermore, the CardioMotion method presents a high specificity of 82.5%. Impact Statement: CardioMotion enables the high throughput identification of small molecule compounds with potential cardiac liabilities, including structural cardiovascular toxicants, with high sensitivity and specificity based solely on the effect of compounds on the spontaneous beating of iPSc derived cardiomyocytes.

30 September 2008 in Toxicologic Pathology
Verified
Journal Article
Open access
PDF file
DDDeidre A. Dalmas
Deidre A. Dalmas
LTLauren A. Tierney
Lauren A. Tierney
CZCindy Zhang
Cindy Zhang
PNPadma K. Narayanan
Padma K. Narayanan
RBRogely W. Boyce
Rogely W. Boyce
MSMarshall S. Scicchitano
Marshall S. Scicchitano
In rodents, p38 MAP kinase inhibitors (p38is) induce bone marrow hypocellularity and reduce reticulocyte and erythrocyte counts. To identify target cell populations affected, a differentiating primary liquid erythroid culture system using sca-1+cells from mouse bone marrow was developed and challenged with p38is SB-203580, SB-226882, and SB-267030. Drug-related alterations in genes involved at different stages of erythropoiesis, cell-surface antigen expression (CSAE), burst-forming unit erythroid (BFU-E) colony formation, and cellular morphology (CM), growth (CG), and viability were evaluated. CSAE, CM, and decreases in BFU-E formation indicated delayed maturation, while CG and viability were unaffected. Terminal differentiation was delayed until day 14 versus day 7 in controls. CSAE demonstrated higher percentages of sca-1+cells after day 2 and reduced percentages of ter119+ cells after day 7 in all treated cultures. Real-time reverse transcriptase polymerase chain reaction revealed a transient delay in expression of genes involved at early, intermediate, and late stages of erythropoiesis, followed by rebound expression at later time points. Results demonstrate p38is do not irreversibly inhibit erythrogenesis but induce a potency-dependent, transient delay in erythropoietic activity. The delay in activity is suggestive of effects on sca-1+bone marrow cells caused by alterations in expression of genes related to erythroid commitment and differentiation resulting in delayed maturation.

1 September 2012 in Toxicology in Vitro
Verified
Journal Article
Closed access
DWDeidre A. Dalmas Wilk
Deidre A. Dalmas Wilk
MSMarshall S. Scicchitano
Marshall S. Scicchitano
DMDiane Morel
Diane Morel